Accentus Cardiac is a privately owned new venture focused on commercialisation of Agluna®,a cost effective silver ion based anti-microbial technology, in the cardiac implantable electronic device (CIED) market. Already being successfully commercialised in the orthopaedic device m
arket, Agluna® is targeted towards the growing unmet clinical
need of post-operative infection in cardiac device surgery. The technology has demonstrated very encouraging clinical efficacy over several years in the orthopaedic limb salvage market, and Accentus now plans to broaden the clinical application of Agluna® through commercial partnerships in the CIED market.
